If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Fair assessment Tommy. I agree RM bashing pointless, although he said trust us (Synairgen BoD), so he'll need to come up with the goods!! Assuming no news, IMO he should update the market at the end of the summer on what's looking likely and timescales etc.
GLA
Size82
Obviously the Activ data release is their best guess and they’ve had to modify that guess once. The trial will decide ultimately when to release it but end of Sept seems possible maybe even likely. I would just caution people against posts that say “RM has had 6 months to sort out this mess” without explaining how they expect the “mess” to get sorted.
It seems to me the only solution is a trial and the most likely candidate is in the U.S. As those trials haven’t started yet it’s clear 6 months is a completely arbitrary idea based upon hot air and wishful thinking.
Tommy,
Re. Timescales. Synairgen reported Activ 2 data would be released this 'summer' and I can't see us getting on a USA funded platform trial prior to its release. It could be released simultaneously though I guess.
Synairgen picked the 'summer' timescale and can only be judged on it, although it is obviously out of their control. While I obviously hope it's not the case, I wouldn't be surprised if it doesn't materalise as it was so unspecific. Felt like a guess.
However, given the 'summer' timescale for Activ 2 I'll expect an update from RM at the end of Sept. if we haven't had news by then.
In terms of treating patients on a platform trial this winter (maybe starting November?!) you would expect Synairgen to be informed prior so if we are actually going to make a platform trial this 'winter' you'd think we should realistically know a bit earlier, October / November at the latest. Just seems logical. Stand to be corrected.
As ever agree on a large amount of patience being required.
GLA
Timescales
The company envisage treating patients on a trial over winter. This trial is clearly NOT controlled by Synairgen. So no matter what people tell you about lack of news this month or even next month. Only the trial coordinators can inform us about inclusion and it’s up to them when they do that. Synairgen can only be judged on the time frame they set of Winter and we’re a long way from that.
Peer review, we were told at the AGM the article had been delivered but typical timescales for a peer review are several months and the publication date is not up to Synairgen. I would suggest end of Sept
we should query if not published.
Long covid, we were told would follow peer review. Remember this is data being gathered from the P3 trial across multiple continents and from various patient languages. We also no they were re-engaging p2 patients. We also seen tender documents from organisations in Europe towards this analysis. It’s a huge task that won’t necessarily be completed in the
timeframes some are putting forward.
The most important with regards to trials is our Activ data which “may” lead to another trial known in the US as strive. We know from the public pronouncements of the team that enrolment is scheduled to start in August. We don’t know if we’re on this trial ornamental f we are, whether we’re the first drugs on this trial.
Again any announcement is not within our control.
Be patient and judge the company on the timeframes above not on the repeated attempts to suggest something may be happening soon when the company have made no such promise.
Remember we have funds to continue until “at least” the July period next year and if we’re on a free trial the amount of funds needed to keep the company going to the end of a trial is minimal. We will have financials that will answer those questions over the next few months.
Stay positive and ignore the attempts to drive down sentiment
ATB
The company are working towards
New trials
Activ data release
Presentation for peer review
We have two international conference presentations coming up in the US and Europe
A new hiring
Long Covid data
The goal is to promote positive sentiment.
ATB for a great week